A Gut Feeling About the Future of Healthcare

Scott Magness, Chief Scientific Officer at Altis Biosystems, discusses the impact that RepliGut®—a human stem cell-derived platform that recreates the intestinal epithelium—may have on stem cell research and drug testing.

Watch the Video

INCREASING THE EFFICIENCY OF DRUG DEVELOPMENT WITH PRECLINICAL TESTING USING HUMAN INTESTINAL STEM CELLS

Due to a lack of robust in vivo gut models, animal studies are generally required to evaluate gut toxicity. However,these studies can be lengthy and expensive and may not accurately recapitulate the behavior of the human gastrointestinal tract. Drugs are thus often developed with undesired gut side effects that are not apparent until clinical trials...

Read More

Characterization of a Novel Human Primary Intestinal Epithelial Monolayer Platform in Response to Cytokine Challenge (Poster)

The ability to grow and expend primary human epithelial cells in vitro has been a significant advancement in the field of gastrointestinal biology. The ALTIS RepliGut® Planar system uses a proprietary biomimetic scaffold on a porous membrane to form a human intestinal epithelial monolayer...

Read More

Accelerating Drug Development with Microphysiological Systems (MPS)

Current preclinical testing using assays based on cancer cells and animal models often results in high failure rates for drug candidates in the clinic. Microphysiological systems like Altis’s RepliGut™ human intestinal tissue model more accurately reflect human physiological environments, enabling more efficient and cost-effective drug discovery and development.

Read More

Altis Biosystems Announces Completion of a $3.1 Million Seed Investment Led by VentureSouth

CHAPEL HILL, N.C. -- Altis Biosystems ("Altis") today announced completion of a seed series investment that was oversubscribed by nearly 50%, raising $3.1 million.

Read More